Mucopolysaccharidosis Type VII (Sly Syndrome): Beta-Glucuronidase Enzyme Activity, Leukocytes

<table>
<thead>
<tr>
<th>Test Code:</th>
<th>LQ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Turnaround time:</td>
<td>7 days - 10 days</td>
</tr>
<tr>
<td>CPT Codes:</td>
<td>82657 x1</td>
</tr>
</tbody>
</table>

**Condition Description**

MPS VII is a disease that affects the breakdown of dermatan sulfate and heparan sulfate. Like other lysosomal storage disorders, severity varies among individuals. Onset may be in the prenatal period with hydrops fetalis. Clinical symptoms include postnatal growth deficiency, macrocephaly, coarse facies, hearing loss, variable corneal opacities, valvular heart disease, hepatosplenomegaly, dysostosis multiplex, hydrocephalus and hirsutism. Development is usually slowed by 1-3 years of age followed by progressive neurodegeneration until death.

For further information about lysosomal storage diseases, please call the Emory Lysosomal Storage Disease Center at (404) 778-8565 or (800) 200-1524. For general questions, call EGL Genetics at 470-378-2200.

**Indications**

This test is indicated for children or adults with symptoms of MPS VII (B-glucuronidase deficiency).

**Methodology**

Fluorometric Enzyme Assay using artificial 4-MU substrate. Beta-glucuronidase is evaluated to confirm a diagnosis of MPS VII.

**Specimen Requirements**

**Type: Whole Blood**

Specimen Requirements:

In sodium heparin (green top) tube: 3-5 ml

Specimen Collection and Shipping: Ship sample at room temperature for receipt at EGL within 24 hours of collection. Do not refrigerate or freeze.

**Related Tests**

- Mucopolysaccharide screen, GAG’s (GA)
- Lysosomal enzyme screening panel (LS)